Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Pharmacokinetics of Prucalopride in Paediatric Subjects, With Functional Faecal Retention

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a confirmed diagnosis of FFR, defined as a minimum 2-month history of faecal impaction, plus at least one of the following:~  * \< 3 bowel movements per week at the toilet;~ * A history of soiling;~* Male and female subjects ≥ 4 to ≤ 12 years of age, with a Tanner stage 1 of 2 or less;~* Weight-height proportionality for age within the 5th and 95th percentile;~* Written informed consent, signed by the subject's legal guardian and by the investigator, and;~* Subject assent documented in the form of a note-to-file in the subject's source documentation.~Exclusion Criteria:~* Requirement for any medication during the period of the trial;~* Evidence by examination or laboratory tests of abnormal growth;~* An abnormal neurologic examination;~* Cystic fibrosis;~* History of, or current anorectal malformations;~* Diagnosed chromosomal abnormalities (e.g., Down's Syndrome);~* Disease state or surgery known to significantly affect the gastrointestinal absorption of drugs, or the assessment of the trial drug's effect;~* Any history, clinical and/or biochemical evidence of clinically significant renal or liver disease or cirrhosis;~* Clinically significant anaemia;~* Use of any investigational drug within the 4-week period prior to administration of trial medication.

- Gender: None
- Minimum Age: 4 Years
- Maximum Age: 12 Years
- Healthy Volunteers: None

Study Arms:
- prucalopride (Type: EXPERIMENTAL): single dose 0.03 mg/kg prucalopride open label

Based on this trial design, predict the completion outcome and termination type (if applicable).